
José Fernando Vilela-Martin

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/938008/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes. New England Journal of Medicine, 2013, 369, 1327-1335.	27.0	2,261
2	Diretrizes Brasileiras de Hipertensão Arterial – 2020. Arquivos Brasileiros De Cardiologia, 2021, 116, 516-658.	0.8	340
3	Prevalence of Metabolic Syndrome: Association with Risk Factors and Cardiovascular Complications in an Urban Population. PLoS ONE, 2014, 9, e105056.	2.5	98
4	Is There an Association between Periodontitis and Hypertension?. Current Cardiology Reviews, 2014, 10, 355-361.	1.5	82
5	Hypertensive crisis: clinical–epidemiological profile. Hypertension Research, 2011, 34, 367-371.	2.7	78
6	Characteristics of resistant hypertension: ageing, body mass index, hyperaldosteronism, cardiac hypertrophy and vascular stiffness. Journal of Human Hypertension, 2011, 25, 532-538.	2.2	68
7	Guidelines on the management of arterial hypertension and related comorbidities in Latin America. Journal of Hypertension, 2017, 35, 1529-1545.	0.5	58
8	Effectiveness of Chlorthalidone Plus Amiloride for the Prevention of Hypertension: The PREVERâ€Prevention Randomized Clinical Trial. Journal of the American Heart Association, 2016, 5, .	3.7	47
9	Non-dipping pattern relates to endothelial dysfunction in patients with uncontrolled resistant hypertension. Journal of Human Hypertension, 2011, 25, 656-664.	2.2	41
10	Gene Variation in Resistant Hypertension: Multilocus Analysis of the Angiotensin 1-Converting Enzyme, Angiotensinogen, and Endothelial Nitric Oxide Synthase Genes. DNA and Cell Biology, 2011, 30, 555-564.	1.9	30
11	l posicionamento brasileiro sobre hipertensão arterial resistente. Arquivos Brasileiros De Cardiologia, 2012, 99, 576-585.	0.8	27
12	Prevention of hypertension in patients with pre-hypertension: protocol for the PREVER-prevention trials, 2011, 12, 65.	1.6	26
13	Disfunção cognitiva após cirurgia cardÃaca. Brazilian Journal of Cardiovascular Surgery, 2008, 23, 245-255.	0.6	17
14	Angiotensin-converting enzyme insertion/deletion polymorphism, 24-h blood pressure profile and left ventricular hypertrophy in hypertensive individuals: a cross-sectional study. European Journal of Medical Research, 2015, 20, 74.	2.2	17
15	Effectiveness of chlorthalidone/amiloride versus losartan in patients with stage I hypertension. Journal of Hypertension, 2016, 34, 798-806.	0.5	17
16	Effect of vildagliptin versus glibenclamide on endothelial function and arterial stiffness in patients with type 2 diabetes and hypertension: a randomized controlled trial. Acta Diabetologica, 2018, 55, 1237-1245.	2.5	17
17	Plasma levels of matrix metalloproteinase-9 are elevated in individuals with hypertensive crisis. BMC Cardiovascular Disorders, 2020, 20, 132.	1.7	17
18	Spotlight on valsartan–sacubitril fixed-dose combination for heart failure: the evidence to date. Drug Design, Development and Therapy, 2016, 10, 1627.	4.3	16

#	Article	IF	CITATIONS
19	Evidence-Based Therapy Prescription in High-Cardiovascular Risk Patients: The REACT Study. Arquivos Brasileiros De Cardiologia, 2013, 100, 212-220.	0.8	14
20	l Luso-Brazilian Positioning on Central Arterial Pressure. Arquivos Brasileiros De Cardiologia, 2017, 108, 100-108.	0.8	13
21	Carotid intima-media thickness is associated with cognitive deficiency in hypertensive patients with elevated central systolic blood pressure. Cardiovascular Ultrasound, 2012, 10, 41.	1.6	11
22	Controlled Versus Uncontrolled Resistant Hypertension: Are They in the Same Bag?. Current Hypertension Reports, 2018, 20, 26.	3.5	11
23	Effect of transcutaneous electrical nerve stimulation on peripheral to central blood pressure ratio in healthy subjects. Clinical Physiology and Functional Imaging, 2016, 36, 293-297.	1.2	10
24	Coronary emergency and diabetes as manifestations of pheochromocytoma. International Journal of Cardiology, 2010, 139, e39-e41.	1.7	9
25	How to Investigate the Vascular Changes in Resistant Hypertension. Current Hypertension Reviews, 2016, 12, 139-147.	0.9	9
26	DPP-4 Inhibitor Reduces Central Blood Pressure in a Diabetic and Hypertensive Patient. Medicine (United States), 2015, 94, e1068.	1.0	8
27	Posicionamento Brasileiro sobre Hipertensão Arterial Resistente – 2020. Arquivos Brasileiros De Cardiologia, 2020, 114, 576-596.	0.8	8
28	Prevalence of Physical Inactivity and its Effects on Blood Pressure and Metabolic Parameters in a Brazilian Urban Population. International Journal of Cardiovascular Sciences, 2018, , .	0.1	8
29	Posicionamento Luso-Brasileiro de Emergências Hipertensivas – 2020. Arquivos Brasileiros De Cardiologia, 2020, 114, 736-751.	0.8	8
30	Pharmacologic Treatment for Prehypertension: To Treat or Not to Treat?. Recent Patents on Cardiovascular Drug Discovery, 2009, 4, 133-141.	1.5	7
31	Fatores associados ao aumento no Ândice de incremento de pressão radial em indivÃduos hipertensos. Arquivos Brasileiros De Cardiologia, 2011, 97, 241-248.	0.8	7
32	A comparison between diuretics and angiotensin-receptor blocker agents in patients with stage I hypertension (PREVER-treatment trial): study protocol for a randomized double-blind controlled trial. Trials, 2011, 12, 53.	1.6	7
33	Nebivolol reduces central blood pressure in stage I hypertensive patients: experimental single cohort study. Sao Paulo Medical Journal, 2014, 132, 290-296.	0.9	7
34	Effects of acute blood pressure elevation on biochemical-metabolic parameters in individuals with hypertensive crisis. Clinical and Experimental Hypertension, 2017, 39, 553-561.	1.3	7
35	Blockade of Renin Angiotensin System in Heart Failure Post-Myocardial Infarction: What is the Best Therapy?. Recent Patents on Cardiovascular Drug Discovery, 2015, 9, 28-37.	1.5	7
36	Avaliação do Seguimento de 1 Ano dos Pacientes IncluÃdos no Registro da Prática ClÃnica em Pacientes de Alto Risco Cardiovascular (REACT). Arquivos Brasileiros De Cardiologia, 2020, 116, 108-116.	0.8	7

#	Article	IF	CITATIONS
37	Twelve-week randomized study to compare the effect of vildagliptin vs. glibenclamide both added-on to metformin on endothelium function in patients with type 2 diabetes and hypertension. Diabetology and Metabolic Syndrome, 2015, 7, 70.	2.7	6
38	Effectiveness of chlorthalidone/amiloride versus losartan in patients with stage I hypertension and diabetes mellitus: results from the PREVER-treatment randomized controlled trial. Acta Diabetologica, 2021, 58, 215-220.	2.5	6
39	Endothelial Changes in Individuals with Prehypertension. Current Hypertension Reviews, 2016, 12, 134-138.	0.9	6
40	Effectiveness of low-dose diuretics for blood pressure reduction to optimal values in prehypertension. Journal of Hypertension, 2018, 36, 933-938.	0.5	5
41	Chlorthalidone Plus Amiloride Reduces the Central Systolic Blood Pressure in Stage 1 Hypertension Patients. Cardiology Research, 2016, 7, 196-201.	1.1	5
42	Factors associated with impaired urinary albumin excretion in hypertensive individuals. International Journal of Cardiology, 2010, 145, 329-331.	1.7	4
43	Renin Angiotensin System Blockage Associates with Insertion/Deletion Polymorphism of Angiotensin-Converting Enzyme in Patients with Hypertensive Emergency. DNA and Cell Biology, 2013, 32, 541-548.	1.9	4
44	Effects of transcutaneous electrical nerve stimulation (TENS) on arterial stiffness and blood pressure in resistant hypertensive individuals: study protocol for a randomized controlled trial. Trials, 2016, 17, 168.	1.6	4
45	Resistant Hypertension On Treatment (ResHypOT): sequential nephron blockade compared to dual blockade of the renin-angiotensin-aldosterone system plus bisoprolol in the treatment of resistant arterial hypertension â€ ^{€°} study protocol for a randomized controlled trial. Trials, 2018, 19, 101.	1.6	4
46	<p>Randomized Study Comparing Vildagliptin vs Glibenclamide on Glucose Variability and Endothelial Function in Patients with Type 2 Diabetes Mellitus and Hypertension</p> . Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2020, Volume 13, 3221-3229.	2.4	3
47	Predictive Factors for Target Organ Injuries in Hypertensive Individuals. Integrated Blood Pressure Control, 2021, Volume 14, 113-121.	1.2	3
48	CRISES HIPERTENSIVAS: DEFININDO A GRAVIDADE E O TRATAMENTO. Revista Da Sociedade De Cardiologia Do Estado De São Paulo, 2018, 28, 254-259.	0.2	3
49	Do thiazide diuretics reduce central systolic blood pressure in hypertension?. Journal of Clinical Hypertension, 2018, 20, 133-135.	2.0	2
50	INFLUENCE OF ANTIHYPERTENSIVE TREATMENT ON MMP-9 LEVELS IN CONTROLLED HYPERTENSIVE INDIVIDUALS. Journal of Hypertension, 2018, 36, e46.	0.5	2
51	CIRCULATING LEVELS OF MATRIX METALLOPROTEINASE-9 ARE ELEVATED IN INDIVIDUALS WITH HYPERTENSIVE CRISIS. Journal of Hypertension, 2018, 36, e164-e165.	0.5	1
52	May Measurement Month 2018: an analysis of blood pressure screening results from Brazil. European Heart Journal Supplements, 2020, 22, H26-H29.	0.1	1
53	Evidence of Nonadherence in Cases of Pseudoresistant Hypertension. Integrated Blood Pressure Control, 2021, Volume 14, 9-17.	1.2	1
54	Dissecção aguda de aorta como apresentação de emergência hipertensiva. Brazilian Journal of Cardiovascular Surgery, 2008, 23, 586-588.	0.6	1

#	Article	IF	CITATIONS
55	Linear and non-linear analyses of autonomic modulation in uncontrolled and controlled elderly resistant hypertensives. Experimental Gerontology, 2022, 159, 111686.	2.8	1
56	Hyperglycemia in patients with hypertensive crisis: Response to ?Hypertensive crisis: Comparison between diabetics and non-diabetics?. International Journal of Cardiology, 2012, 154, 378.	1.7	0
57	Urinary albumin excretion regression in hypertensive individuals. International Journal of Cardiology, 2012, 157, 144-146.	1.7	0
58	PP.20.30. Journal of Hypertension, 2015, 33, e315.	0.5	0
59	PP.28.15. Journal of Hypertension, 2015, 33, e378.	0.5	0
60	[PP.21.02] INDIVIDUALS WITH HYPERTENSIVE EMERGENCY PRESENT ASSOCIATION BETWEEN RENAL DYSFUNCTION AND INFLAMMATORY CYTOKINES. Journal of Hypertension, 2016, 34, e245.	0.5	0
61	[PP.36.12] METABOLIC CHANGES, BIOMARKERS OF ENDOTHELIAL DYSFUNCTION AND COAGULATION FACTORS ARE PRESENT IN INDIVIDUALS WITH HYPERTENSIVE CRISIS. Journal of Hypertension, 2016, 34, e339.	0.5	0
62	Vascular Peripheric Differences In Patients With Chagas Versus Ischemic Heart Failure. Medicine and Science in Sports and Exercise, 2017, 49, 817.	0.4	0
63	The more individualised the blood pressure, the better. Journal of Public Health and Emergency, 2017, 1, 71-71.	4.4	0
64	EFFECT OF SEQUENTIAL NEPHRON BLOCKING IN COMPARISON WITH THE DOUBLE BLOCKADE OF THE RENIN- ANGIOTENSIN SYSTEM + BISOPROLOL ON CENTRAL SYSTOLIC BLOOD PRESSURE AND ARTERIAL STIFFNESS. Journal of Hypertension, 2021, 39, e354.	0.5	0
65	Central Hemodynamic Parameters are Altered in Resistant Hypertensive Individuals. Artery Research, 2019, 25, 101-105.	0.6	0
66	SAT-141 Effect of Vildagliptin versus Glibenclamide on Glycemic Variability and Endothelial Function in Individuals with Type 2 Diabetes and Hypertension: A Randomized Controlled Trial. Journal of the Endocrine Society, 2019, 3, .	0.2	0
67	Lifestyle changes counseling reduces central blood pressure in pre-hypertensive individuals: an intervention study. Revista De Educação FÃsica / Journal of Physical Education, 2019, 88, .	0.1	0
68	POSICIONAMENTO BRASILEIRO SOBRE HIPERTENSÃ∱O ARTERIAL RESISTENTE – 2020. Revista Brasileira De Hipertensão, 2020, 27, 41-58.	0.1	0
69	Parameters of Central Hemodynamics as New Biomarkers of Cardiovascular Risk. Arquivos Brasileiros De Cardiologia, 2020, 115, 1133-1134.	0.8	0
70	Alterations in pro- and anti-inflammatory mediators are involved in microvascular dysfunction in postmenopausal women with type 2 diabetes mellitus. Brazilian Journal of Medical and Biological Research, 2022, 55, e11821.	1.5	0